In last trading session, Standard BioTools Inc (NASDAQ:LAB) saw 1.28 million shares changing hands with its beta currently measuring 1.81. Company’s recent per share price level of $1.18 trading at $0.09 or 8.26% at ring of the bell on the day assigns it a market valuation of $447.21M. That closing price of LAB’s stock is at a discount of -157.63% from its 52-week high price of $3.04 and is indicating a premium of 16.1% from its 52-week low price of $0.99. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.26 million shares which gives us an average trading volume of 1.94 million if we extend that period to 3-months.
For Standard BioTools Inc (LAB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.67. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Standard BioTools Inc (NASDAQ:LAB) trade information
Upright in the green during last session for gaining 8.26%, in the last five days LAB remained trading in the red while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $1.18 price level, adding 2.48% to its value on the day. Standard BioTools Inc’s shares saw a change of -32.57% in year-to-date performance and have moved -0.84% in past 5-day. Standard BioTools Inc (NASDAQ:LAB) showed a performance of 11.32% in past 30-days. Number of shares sold short was 15.73 million shares which calculate 6.69 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3.25 to the stock, which implies a rise of 63.69% to its current value. Analysts have been projecting 3.25 as a low price target for the stock while placing it at a high target of 3.25. It follows that stock’s current price would drop -175.42% in reaching the projected high whereas dropping to the targeted low would mean a loss of -175.42% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 11.61% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 65.38% while estimates for its earnings growth in next 5 years are of 57.47%.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
Insiders are in possession of 1.86% of company’s total shares while institution are holding 73.11 percent of that, with stock having share float percentage of 74.49%. Investors also watch the number of corporate investors in a company very closely, which is 73.11% institutions for Standard BioTools Inc that are currently holding shares of the company. CASDIN CAPITAL, LLC is the top institutional holder at LAB for having 63.96 million shares of worth $113.21 million. And as of 2024-06-30, it was holding 17.1782 of the company’s outstanding shares.
The second largest institutional holder is VIKING GLOBAL INVESTORS LP, which was holding about 58.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.7524 of outstanding shares, having a total worth of $103.81 million.
